TSX •
Healthcare •
Biotechnology •
Quote as of 05/21/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTSX
Market Capitalization45.05 mln
Float65.95 mln
Earnings Date06/25/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.02
Debt-free
ROE
-96.01
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Medicenna Therapeutics Corp. is a Toronto-based medical company focused on developing new treatments for cancer, inflammation, and immune-related diseases. Its lead drug candidate targets recurrent glioblastoma, an aggressive form of brain cancer, while its broader pipeline includes therapies designed to strengthen the immune system's ability to fight tumors and others aimed at calming harmful immune responses in conditions like multiple sclerosis. The company's approach centers on engineering enhanced versions of naturally occurring immune proteins to improve their precision and effectiveness.
